Compositions, articles and methods for treating sleeplessness, anxiety, pain or inflammation include: (i) one or more pharmacologically active, non-psychoactive cannabinoids; (ii) one or more active agents; and an optional carrier or matrix. The optional carrier or matrix may comprise ingredients such as solvents, solid or dissolvable supports, fillers, flavorants, flavor or taste masking agents, and other adjuvants that provide the composition in a useful form factor configured for easy administration to a mammal of an appropriate pharmacological dosage of the active ingredients.

Compositions, articles and methods for treating sleeplessness, anxiety, pain or inflammation include: (i) one or more pharmacologically active, non-psychoactive cannabinoids; (ii) one or more active agents; and an optional carrier or matrix. The optional carrier or matrix may comprise ingredients such as solvents, solid or dissolvable supports, fillers, flavorants, flavor or taste masking agents, and other adjuvants that provide the composition in a useful form factor configured for easy administration to a mammal of an appropriate pharmacological dosage of the active ingredients.

The present disclosure provides methods of treating lysosomal storage disorders (LSDs) in a subject in need thereof by administering a combination of acetyl-leucine and miglustat to the subject, wherein subject is naive to treatment with miglustat.

The present disclosure provides methods of treating lysosomal storage disorders (LSDs) in a subject in need thereof by administering a combination of acetyl-leucine and miglustat to the subject, wherein subject is naive to treatment with miglustat.

Provided herein are methods of treating, inhibiting, reducing, or ameliorating cardiovascular adverse events in a patient caused by administration of carfilzomib by administering to the patient at least one of a soluble guanylyl cyclase (sGC) activator, a PDE5 inhibitor, p38 inhibitor, and/or MAPKAPK-2 inhibitor.

Provided herein are methods of treating, inhibiting, reducing, or ameliorating cardiovascular adverse events in a patient caused by administration of carfilzomib by administering to the patient at least one of a soluble guanylyl cyclase (sGC) activator, a PDE5 inhibitor, p38 inhibitor, and/or MAPKAPK-2 inhibitor.

Provided herein are methods of treating, inhibiting, reducing, or ameliorating cardiovascular adverse events in a patient caused by administration of carfilzomib by administering to the patient at least one of a soluble guanylyl cyclase (sGC) activator, a PDE5 inhibitor, p38 inhibitor, and/or MAPKAPK-2 inhibitor.

This present invention and its embodiments relates to methods for reducing pain during photodynamic therapy of actinic keratosis. The present invention also relates to methods of treating actinic keratosis with reduced pain during photodynamic therapy of actinic keratosis.

Disclosed is a piglet feed based on bacteria enzyme synergistic fermentation process. The piglet feed is composed of basic components and bacteria enzyme synergistic fermentation feed. Basic components include soybean protein concentrate, whey powder, fish meal, sodium chloride, choline chloride, stone powder, calcium hydrogen phosphate, composite vitamins, composite trace elements, and composite amino acids. The bacterial enzyme synergistic fermentation feed includes a fermentation substrate, an enzyme preparation, and a bacterial strain. The bacterial enzyme synergistic fermentation feed can not only improve the production performance of piglets, but also improve the utilization rate of feed nutrients, especially the utilization rate of feed phosphorus, thereby reducing the excretion of phosphorus in feces.

Disclosed is a piglet feed based on bacteria enzyme synergistic fermentation process. The piglet feed is composed of basic components and bacteria enzyme synergistic fermentation feed. Basic components include soybean protein concentrate, whey powder, fish meal, sodium chloride, choline chloride, stone powder, calcium hydrogen phosphate, composite vitamins, composite trace elements, and composite amino acids. The bacterial enzyme synergistic fermentation feed includes a fermentation substrate, an enzyme preparation, and a bacterial strain. The bacterial enzyme synergistic fermentation feed can not only improve the production performance of piglets, but also improve the utilization rate of feed nutrients, especially the utilization rate of feed phosphorus, thereby reducing the excretion of phosphorus in feces.